Delving into the Latest Updates on R.W. Johnson Pharmaceutical Research Institute with Synapse

Overview

Tags

Nervous System Diseases

Immune System Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

Potassium channel x Sodium channels	1
ADRA2(Adrenergic receptors alpha-2)	1
p38 MAPK(P38 mitogen-activated protein kinase)	1

The purpose of this study is to determine the efficacy and safety of topiramate (96 mg or 192 mg daily) as compared to placebo in maintaining weight loss in obese subjects who participated in an eight week intensive non-pharmacologic weight loss program.
The primary efficacy endpoint will be the percent change in body weight from enrollment visit to week 60.

Start Date01 Aug 2000

Sponsor / Collaborator

University of Copenhagen

[+1]

100 Clinical Results associated with R.W. Johnson Pharmaceutical Research Institute

Login to view more data

0 Patents (Medical) associated with R.W. Johnson Pharmaceutical Research Institute

Login to view more data

682

Literatures (Medical) associated with R.W. Johnson Pharmaceutical Research Institute

01 Dec 2007·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Drugs Designed To Inhibit Human p38 Mitogen-Activated Protein Kinase Activation TreatToxoplasma gondiiandEncephalitozoon cuniculiInfection

Q2 · MEDICINE

Article

Author: Khan, Imtiaz A. ; Daniel, Benjamin J. ; Siekierka, John ; Wadsworth, Scott ; Curiel, Tyler J. ; Brumlik, Michael J. ; Burow, Matthew E. ; Zou, Weiping ; Wei, Shuang

ABSTRACTWe recently showed that the pyridinylimidazoles SB203580 and SB202190, drugs designed to block human p38 mitogen-activated protein kinase (MAPK) activation, also inhibited replication of the medically important intracellular parasiteToxoplasma gondiiin cultured human fibroblasts through a direct effect on the parasite. We now show that additional pyridinylimidazole and imidazopyrimidine p38 MAPK inhibitors inhibit intracellularT. gondiireplication in vitro and protect mice against fatalT. gondiiinfection. Mice surviving infection following treatment with p38 MAPK inhibitors were resistant to subsequentT. gondiichallenge, demonstrating induction of protective immunity. Thus, drugs originally developed to block human p38 MAPK activation are useful for treatingT. gondiiinfection without inducing significant immunosuppression. MAPK inhibitors combined with either of the approved anti-Toxoplasmadrugs sulfadiazine and pyrimethamine resulted in improved survival among mice challenged with a fatalT. gondiiinoculum. A MAPK inhibitor also treated mice infected with theMicrosporidiumparasiteEncephalitozoon cuniculi, suggesting that MAPK inhibitors represent a novel class of agents that may have a broad spectrum of antiparasitic activity. Preliminary studies implicate aT. gondiiMAPK homologue as the target of drug action, suggesting possibilities for more-selective agents.

01 Dec 2004·Journal of Endotoxin Research

p38-MAPK inhibition and endotoxin induced tubular dysfunction in men

Article

Author: Jaap E. Tulleken ; Peter de Boer ; Jan G. Zijlstra ; Tjip S. van der Werf ; Jack J.M. Ligtenberg

BACKGROUNDTo evaluate the possibility of preventing endotoxin induced renal damage by p38-MAPK inhibition in a human model.DESIGN AND METHODSTwenty-one healthy young male volunteers received 4 ng/kg Escherichia coli endotoxin as a single dose. Four groups of volunteers received an oral dose of placebo or 350, 700 or 1400 mg RWJ-67657, a p38-MAPK inhibitor, 20 min before endotoxin infusion. Urine samples were collected at set time intervals. The urinary excretion rate of beta(2)-microglobulin and N-acetyl-beta-D-glucosaminidase, as indicators of tubular dysfunction was determined.RESULTSThere was a significant increase of beta(2)-microglobulin and N-acetyl-beta-D-glucosaminidase urine excretion rate after endotoxin infusion in the placebo group. p38-MAPK inhibition prevented the increase of markers for tubulopathy.CONCLUSIONSEndotoxin infusion induces measurable tubular damage. Blocking the p38-MAPK may prevent this damage. The mechanism is unclear, but blocking TNF-alpha release is a possible explanation.

01 Dec 2004·Journal of Endotoxin Research

p38-MAPK inhibition and endotoxin induced tubular dysfunction in men

Author: Zijlstra, Jan G. ; Ligtenberg, Jack J.M. ; van der Werf, Tjip S. ; de Boer, Peter ; Tulleken, Jaap E.

Background: To evaluate the possibility of preventing endotoxin induced renal damage by p38-MAPK inhibition in a human model. Design and Methods: Twenty-one healthy young male volunteers received 4 ng/kg Escherichia coli endotoxin as a single dose. Four groups of volunteers received an oral dose of placebo or 350, 700 or 1400 mg RWJ-67657, a p38-MAPK inhibitor, 20 min before endotoxin infusion. Urine samples were collected at set time intervals. The urinary excretion rate of β2-microglobulin and N-acetyl-β-D-glucosaminidase, as indicators of tubular dysfunction was determined. Results: There was a significant increase of β2-microglobulin and N-acetyl-β-D-glucosaminidase urine excretion rate after endotoxin infusion in the placebo group. p38-MAPK inhibition prevented the increase of markers for tubulopathy. Conclusions: Endotoxin infusion induces measurable tubular damage. Blocking the p38-MAPK may prevent this damage. The mechanism is unclear, but blocking TNF-α release is a possible explanation.

100 Deals associated with R.W. Johnson Pharmaceutical Research Institute

Login to view more data

100 Translational Medicine associated with R.W. Johnson Pharmaceutical Research Institute

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

Other

31

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

RWJ-68354 ( p38 MAPK )	Inflammatory Bowel Diseases More	Preclinical
RWJ-52353 ( ADRA2 )	Pain More	Preclinical
Carsatrin ( Potassium channel x Sodium channels )	Cardiovascular Diseases More	Discovery
Perflubron Emulsion(Alliance)	Transfusion Reaction More	Discontinued
MC-02306	Enterococcus faecium infection More	Discontinued